Fibroblast growth factor (FGF) signaling plays an important role in lung organogenesis. Over recent decades, FGF signaling in lung development has been extensively studied in animal models. However, little is known about the expression, localization, and functional roles of FGF ligands during human fetal lung development. Therefore, we aimed to determine the expression and function of several FGF ligands and receptors in human lung development. Using in situ hybridization (ISH) and RNA sequencing, we assessed their expression and distribution in native human fetal lung. Human fetal lung explants were treated with recombinant FGF7, FGF9, or FGF10 in air-liquid interface culture. Explants were analyzed grossly to observe differences in branching pattern as well as at the cellular and molecular level. ISH demonstrated that FGF7 is expressed in both the epithelium and mesenchyme; FGF9 is mainly localized in the distal epithelium, whereas FGF10 demonstrated diffuse expression throughout the parenchyma, with some expression in the smooth muscle cells (SMCs). FGFR2 expression was high in both proximal and distal epithelial cells as well as the SMCs. FGFR3 was expressed mostly in the epithelial cells, with lower expression in the mesenchyme, while FGFR4 was highly expressed throughout the mesenchyme and in the distal epithelium. Using recombinant FGFs, we demonstrated that FGF7 and FGF9 had similar effects on human fetal lung as on mouse fetal lung; however, FGF10 caused the human explants to expand and form cysts as opposed to inducing epithelial branching as seen in the mouse. In conjunction with decreased branching, treatment with recombinant FGF7, FGF9, and FGF10 also resulted in decreased double-positive SOX2/SOX9 progenitor cells, which are exclusively present in the distal epithelial tips in early human fetal lung. Although FGF ligand localization may be somewhat comparable between developing mouse and human lungs, their functional roles may differ substantially.
Introduction
Mammalian lungs are complex organs that undergo a series of epithelial branching events, resulting in a very organized stereotypical structure containing 23 generations of branches in humans. The achievement of this outcome requires a series of strictly regulated cellular and molecular events, which include cell migration, changes in cell shape, directed cell division, proximal-distal patterning, and epithelial-mesenchymal crosstalk. Several signaling pathways and transcription factors control these events in mouse lung development, including the WNT, BMP, HH, RA, and HIPPO pathways.
However, in murine lung branching morphogenesis, the Fgf-signaling pathway is one of the most critical regulators.
Several FGF ligands and all four Fgf receptors (Fgfr1-4), alongside splice variants, have been reported in the developing rodent lung [1, 2] . Studies in mice have shown that perturbation of one or more FGF ligands and/or receptors, particularly Fgf9 and Fgf10, can lead to branching defects. For example, deletion of Fgf10, located within the mesoderm, or its receptor Fgfr2IIIb, located within the epithelium, in mouse lung results in complete distal lung agenesis [3, 4] . This highlights the role of Fgf10 as a main regulator of murine lung branching morphogenesis. Moreover, Fgf10 controls proximal-distal patterning in the mouse FGF signaling in human lung development 255 lung by preventing the differentiation of epithelial Sox9 progenitors into Sox2-expressing airway cells [5, 6] . Fgf7 is also produced in the mesenchyme and acts on epithelial Fgfr2IIIb. Fgf10 induces epithelial branching and increases cell migration, whereas Fgf7 induces cell proliferation in vitro causing the epithelium to form cysts but not branch [7] . Deletion or overexpression of Fgf9 in the developing mouse lung results in branching defects, accompanied by perturbation of the HH and Wnt-beta-catenin pathways [8] and the expression of Fgf10 and Bmp4 [9, 10] . Furthermore, deletion of either Fgfr3 or Fgfr4 results in the reduced formation of alveoli, and deletion of both yields hypoplastic lungs and impaired alveologenesis in the postnatal mouse lung [11] . FGF signaling is implicated in many lung diseases and improves disease in many animal models [12] [13] [14] . However, to date, there have been no successful FGF targeting therapies used to treat human lung disease. Differences have been reported during development and disease between mouse and human models [15] , suggesting that alternative supplemental sources to animal models should be sought to achieve translational potential. In particular, human and mouse lungs are different in scale, timing, and structure of conducting airway formation. More recently, we started to uncover other molecular differences between human and mouse lung [16] .
Fgf signaling is both important and necessary in rodent lung branching morphogenesis, whereas the molecular and spatial expression of the different FGFs and their receptors in the developing human lung has not been reported. Consequently, the roles of these signaling pathways in human lung development are unclear. In this study, we aimed to determine the spatial and temporal expression of the different FGF ligands and receptors in the human developing lung, as well as the effect of FGF7, FGF9, and FGF10 on human lung branching in vitro.
Methods

Ethics statement
After informed consent was given, deidentified human fetal samples were collected under Institutional Review Board approval (USC-HS-13-0399 and CHLA-14-2211). The only information collected was gestational age and whether there were any known genetic or structural abnormalities.
Animal experiments were performed under the research protocols (#31-17) approved by the Animal Research Committee at Children's Hospital Los Angeles and in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health.
Explant cultures
Human fetal lung explants between 10 and 12 weeks' gestation, or C57BL6 embryonic day 12.5 for mouse lungs, were cultured on an air-liquid interface as previously described [17] and treated with either FGF ligands or SU5402 (details are provided in supplementary material, Supplementary materials and methods).
Immunohistochemistry
Human lungs or explants were fixed overnight in 4% PFA at 4 ∘ C and processed for staining as previously described [16, 17] . Antibodies and procedures are detailed in supplementary material, Table S1 .
In situ hybridization
Fluorescence in situ hybridization (ISH) was conducted using the Advanced Cell Diagnostics RNAScope Fluorescent Multiplex Assay (Newark, CA, USA) following the manufacturer's instructions (a detailed protocol is provided in supplementary material, Supplementary materials and methods).
Primary human fibroblast cultures
Fresh human fetal tissue (16-18 weeks' gestation) was brought to a single cell suspension by manually chopping the tissue and digesting it in a mixture of DNAse (Cat# DN25-1G; Sigma-Aldrich, St. Louis, MO, USA) and collagenase (Cat# 10103586001; Roche, Indianapolis, IN, USA) in HBSS for 30 min at 37 ∘ C. The enzymatic activity was stopped using 10% FBS in DMEM/F12. Cells were further dissociated using a series of pipettes, syringes, and strainers; treated with red blood cell lysis buffer; washed; and plated on chamber slides or 6-well plates. Cells were allowed to adhere for 45 min, after which they were washed. Adherent cells were then treated with 200 ng/ml of FGF9 or FGF10 for 48 h. Post-treatment, fibroblasts on chamber slides were washed, fixed with 4% PFA, and stained with anti-CDH1 antibody and Cy3-ACTA2 antibody (C6198; Sigma-Aldrich). Fibroblasts in six-well plates were scraped for RNA extraction.
RT-qPCR analyses
RNA was extracted using the iNtRon Biotechnology, Inc.; Easy-Spin™ Total RNA Extraction Kit (Burlington, MA, USA). RNA used was reverse-transcribed into cDNA using the Tetro cDNA Synthesis Kit (Bioline, Taunton, MA, USA) according to the manufacturer's instructions. Dual-color Hydrolysis Probe -Universal probe library-based qPCR, using the LightCycler 480 from Roche Applied Science (Indianapolis, IN, USA), was used with human GAPDH as the reference transcript and specific human primer sequences (listed in supplementary material, Table S2 ).
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obtained with htseq-count (gencode only), and statistics were generated with edgeR. The output from the statistical analysis was annotated with raw counts, reads per kilobase of transcript per million mapped reads (RPKM), and database identifiers using Ensembl BiomaRt. RNA sequencing data can be found using the GEO accession GSE121238. Detailed methods are provided in supplementary materials, Supplementary materials and methods.
Statistical analyses
Statistical analyses were performed using GraphPad Prism (GraphPad Software Inc., La Jolla, CA, USA). Student's t-test, or paired Student's t-test when appropriate, was used to compare two groups. Data are presented as mean ± SEM. The results were considered significant if p ≤ 0.05.
Results
FGF ligands and receptors are widely expressed in the developing human lung
We first sought to determine which FGFs and FGFRs are expressed in the developing human lung. RNA sequencing on native human fetal lung was performed at different periods of gestational development (10.5 weeks = mid-pseudoglandular; 14 weeks = late-pseudoglandular; 20 weeks = mid-canalicular) ( Figure 1A ). Human lung developmental stages are similar to those in mice, although the timing scale is different. The pseudoglandular stage spans 5-17 weeks' gestation, corresponding to murine embryonic days E12-15, whereas the human canalicular stage is 16-26 weeks' gestation, the equivalent of E15-17 in mouse [18] . Our data showed that the canonical FGF ligands FGF9, FGF10, FGF18, and FGF20 were expressed at a higher level in the developing human lung, whereas FGF2, FGF7, FGF16, FGF17, and FGF22 levels were significantly lower ( Figure 1A ). The intracellular FGF ligands FGF12, FGF13, and FGF14 also demonstrated low expression levels throughout human fetal lung development. All of the FGF receptors (FGFR1-4) were strongly expressed throughout the pseudoglandular and canalicular stages, with FGFR4 displaying the highest expression of the four ( Figure 1A) .
Next, we wanted to establish the spatial localization of some of the expressed ligands and receptors, especially those that are most commonly studied in the mouse lung. Using fluorescence ISH on human fetal lung sections, at different gestational stages (11, 14, 16 , and 18 weeks), we found that FGF7 was expressed throughout the tissue in both epithelium and mesenchyme at each gestational age ( Figure 1B ,C,H,I), whereas FGF9 was mostly expressed in the distal epithelial tips and mesothelial cells at each stage, with minimal expression in the proximal epithelium ( Figure 1D ,E,J,K). FGF10 was predominantly expressed in the mesenchyme, both distally and proximally ( Figure 1F ,G,L,M). FGFR4 was expressed in the mesenchyme and the distal epithelium, with an increase in expression from 11 to 14 weeks, as predicted by RNA sequencing ( Figure 1A ), but absent in the proximal epithelium ( Figure 1B ,C,H,I). FGFR3 was strongly expressed in the proximal and distal epithelium, with lower expression in the mesenchyme ( Figure 1D ,E,J,K). Furthermore, FGFR2 was highly expressed in the distal epithelium with low levels in the proximal epithelium ( Figure 1F ,G,L,M). Localization of FGFR2 ( Figure 1N -Q) and FGFR1 ( Figure 1R -U) was also validated using IHC at 11, 14, 16, and 18 weeks. A strong presence of both receptors in the proximal and distal epithelium was seen throughout each stage, but expression in the mesenchyme appeared to decrease in the canalicular stage when compared to the pseudoglandular stage.
FGF7 and FGF9 induce cyst formation in human fetal lung explants, similar to mice Next, we tested the effect of exogenous FGF ligands on human fetal lung explants and compared this to their described effects on mouse explants. Human fetal lung explants between 10 and 12 weeks gestational age and E12 mouse lung explants were cultured on an air-liquid interface as described in the methods. Human explants treated with recombinant human (rh) FGF7 (200 ng/ml) showed enlarged distal buds ( Figure 2D ) compared to control ( Figure 2B ), consistent with cyst formation previously described in mice and shown in Figure 2D ′ versus B ′ . Similarly, rhFGF9 (200 ng/ml) treatment resulted in cyst formation and thickened mesenchyme ( Figure 2F ) compared to control ( Figure 2B ). This effect was similar to what is seen in mouse explants ( Figure 2F ′ versus B ′ ). Quantification of the cystic areas in the human explants confirmed that FGF7 induced a significant increase in cyst area compared to control (*p = 0.0197, Figure 2I ), while FGF9 had a nonsignificant trend toward increased cyst area (p = 0.0662, Figure 2I ). These results are comparable to what is observed in the mouse explants where quantification of the cystic areas after treatment with FGF7 or FGF9 demonstrated a significant increase in cyst area compared to control (p = 0.0121 and 0.0085, respectively, Figure 2J ).
FGF10 does not induce branching in human fetal lung explants
In the presence of rhFGF10 (200 ng/ml), human fetal explants showed enlarged buds ( Figure 2H versus B) compared to control explants (**p = 0.0072, Figure 2I ). Quantification of the number of branches between 0 and 48 h demonstrated a significant decrease in branches compared to controls (*p = 0.0228, Figure 2L ). In contrast, a significant increase (*p = 0.034, Figure 3L Figure 2J ), as previously described [19] . Different concentrations of rhFGF10 (400 and 800 ng/ml; Figure 2K ) were tested on human fetal explants, all of which induced significantly enlarged cyst formation when compared to controls (400 ng/ml: **p = 0.0012, 800 ng/ml: ***p = 0.0015; Figure 2M ) and failed to induce branching post-48 h in culture (400 ng/ml: **p = 0.0115, 800 ng/ml: ***p = 0.0082; Figure 2L ). Later-stage human lung explants (13-14 weeks) treated with FGF10 (200 ng/ml) also displayed significantly enlarged distal buds ( Figure 2N -O, *p = 0.024).
FGF ligands did not affect cell proliferation in human fetal lung explants
In mouse and rat explant models, exogenous FGF ligands induce epithelial or mesenchymal cell proliferation [20, 21] . To test whether this is true for human lung explants, we assessed cell proliferation using immunostaining for Ki67. While FGF7, FGF9, and FGF10 all induced signaling in human explants as shown by Western blot assessment of ERK phosphorylation (p = 0.0678, *p = 0.0028, **p = 0.0266, respectively; Figure 3F ,G), they did not induce any changes in Ki67+ cell numbers ( Figure 3B -D versus A) compared to controls. Quantification of the total number of proliferating cells in the epithelium, the mesenchyme or both combined confirmed that these FGF ligands had no effect on cell proliferation ( Figure 3E ).
FGF treatments altered the coexpression of SOX2/SOX9 double-positive cells
We recently demonstrated that the human lung bud epithelial tips coexpress SOX2 and SOX9 and that this coexpression is required for proper branching in the human fetal lung [16] . Moreover, in mouse lungs, FGF signaling alters the proximal-distal patterning [22] . We therefore assessed the coexpression of SOX2 and SOX9 in the explants treated with the FGF ligands. Following 48 h in culture, control explants displayed coexpression of SOX2 and SOX9 in the distal bud tips ( Figure 4A ). However, treatment with FGF7 and FGF9 resulted in expansion of SOX9 cells and a near absence in expression of SOX2 ( Figure 4B ,C, respectively). Treatment with FGF10 leads to expansion of the SOX9 domain and a decrease in SOX2 expression in the bud tips ( Figure 4D ). RT-qPCR analyses of SOX2 showed decreased expression in the explants treated with FGF9 (*p = 0.026) compared to control, while a nonsignificant trend toward decrease was observed in explants treated with FGF7 and FGF10 ( Figure 4I ). Analyses of known FGF targets by RT-qPCR showed that expression for each gene was significantly increased following FGF7 and FGF9 treatment SPRY2 (*p = 0.0028 and **p = 0.0067), SPRY4 (*p = 0.0003, **p = 0.0030), ETV4 (*p = 0.0002, **p = 0.019), ETV5 (*p = 0.0085, **p = 0.0248), and DUSP6 (*p = 0.0001, **p = 0.0001) [23] [24] [25] [26] [27] , with a minimal increase by FGF10 ( Figure 4J ). In mouse lung explants, Sftpc has been shown as one of the targets of FGF10 [28] . As none of the downstream targets tested showed a significant change in response to FGF10, we sought to determine whether SFTPC could be a target in the human explants. We demonstrated that pro-SFTPC is absent in the human lung at 11.6 weeks ( Figure 4K ) and begins to be expressed at week 14 ( Figure 4L ,M, respectively). Similarly, HTII-280 was absent at 11.6 weeks ( Figure 4K) , with low expression at 14 weeks ( Figure 4L ) and a robust expression at 18.2 weeks ( Figure 4M ). HTII280 did not always colocalize with pro-SFTPC, supporting previous reports that HTII-280 may also be expressed in undifferentiated epithelium [29] . Furthermore, we had previously established that smooth muscle cells (SMCs) appear to promote SOX2+ cells and suppress the SOX9+ population [16] . Given the expansion of SOX9+ cells in the FGF-treated explants, we assessed the expression of SMCs using immunostaining for ACTA2. There was an evident decrease in SMC expression in FGF7, FGF9, and FGF10 treated explants as compared to controls ( Figure 4F -H versus E).
FGF9 inhibits the differentiation of SMCs from human fetal cells, while inhibiting FGF10 expression
In mice, FGF9 inhibits the differentiation of SMCs while inducing Fgf10 expression [10] . Primary cultures of human fetal lung fibroblasts were obtained from lungs between 16 and 18 weeks' gestation and cultured in the absence or presence of 200 ng/ml rhFGF7, rhFGF9, or rhFGF10. Immunofluorescence (IF) staining of treated fibroblasts demonstrated that, similar to mouse fibroblasts, FGF9 triggered a decrease in SMC differentiation, as indicated in the reduced staining for ACTA2 ( Figure 5C versus A), whereas treatment with FGF7 and FGF10 demonstrated no apparent difference 
0085). (K)
Human fetal lung explants (10 weeks) treated with 400 and 800 ng/ml of rhFGF10 for 48 h. (L) Graphs presenting the fold-increase in the number of distal branches following 48 h treatment in rhFGF10 dose-treated human explants and 200 ng/ml rhFGF10 mouse explants (human: n = 9, 200 ng/ml, *p = 0.0228; 400 ng/ml **p = 0.0115; 800 ng/ml, ***p = 0.0082; mouse: n = 3, *p = 0.0342). (M) Graph presenting the area of epithelial buds following 48 h in culture of control and FGF10 dose-treated human explants (200, 400, 800 ng/ml) (n = 5 for each condition; *p = 0.0072; **p = 0.0012; ***p = 0.0015). (N) Human fetal (13.2 weeks) lung explant cultures at t = 0 and t = 48 h in the presence or absence of 200 ng/ml rhFGF10 (n = 3 of each). (O) Graph presenting the area of epithelial buds following 48 h in culture of 13.2-14 weeks' control and FGF10-treated human explants (n = 3 for each, *p = 0.024).
in SMC differentiation compared to control fibroblasts ( Figure 5B,D versus A respectively) . These results were validated by RT-qPCR ( Figure 5E ), where ACTA2 expression was significantly less following FGF9 treatment compared to control (p = 0.0113). However, FGF7 to control fibroblasts (p = 0.0421; Figure 5F ). These results are the opposite of what have been described in mouse fibroblasts [10] .
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FGFR inhibition prevents branching of human fetal lung explants
In order to determine whether global FGF signaling inhibition impairs human fetal lung branching, we treated our explant cultures with SU5402, a tyrosine kinase inhibitor known to inhibit FGFR signaling. Human fetal lung explants (10-12 weeks' gestation) were treated with 10 μM SU5402. The explants treated with SU5402 demonstrated minimal branch formation compared to controls (Figure 6D versus C) . This was validated via quantification of the fold-change in the number of branches between 0 and 48 h, which showed a significant decrease in the number of branches in the human fetal explants treated with SU5402 compared to controls ( Figure 6G , p = 0.0049). Treatment with SU5402 resulted in an expansion of SOX2-expressing cells as opposed to the decrease following FGF treatment, with a near-complete loss of SOX9 expression in the bud tips ( Figure 6F ) compared to the coexpression of SOX2/SOX9 in the control explants ( Figure 6E ).
Discussion
FGF signaling and its role in mouse lung development has been extensively studied; however, its role in human lung development remains unclear. Microarray studies performed on both the developing mouse and human lung reported the expression of several FGFs and their receptors [30, 31] and are in accordance with our RNA sequencing data on the human lung at various gestational stages. For example, FGF18 expression increases significantly from 11 to 14 or 20 weeks' gestation. Moreover, the temporal expression of FGF10 corroborates our previously published data showing that FGF10 expression does not increase during the pseudoglandular stage but increases between the pseudoglandular and canalicular stages [32] . While the spatial expression of FGF7, FGF9, and FGFRs is very similar to that described in mice, the expression of FGF10 differed significantly. In mouse lung, an Fgf10 gradient guides branching morphogenesis, whereby Fgf10 expression is concentrated in the distal mesenchyme near branch buds [33] . ISH performed on human fetal lung samples did not show a concentrated gradient of FGF10 expression but rather a diffuse expression throughout the mesenchyme. This difference could be a timing discrepancy, with the possibility that earlier-stage human lungs may have a localized FGF10 expression. However, the 11-week human fetal lungs that we assessed correspond to mid-pseudoglandular-stage mouse lung (around E13), a period when Fgf10 expression is still localized to bud-neighboring domains. FGF10 expression was also detected in the airway SMCs, similar to mice. Fgf10 is a critical factor in mouse lung branching morphogenesis. Deletion of Fgf10 or its receptor Fgfr2IIIb in mouse lung results in complete lung agenesis [3, 4] . Furthermore, rhFGF10 protein induces branching in E12 embryonic mouse lung and isolated epithelial buds (Figure 2) [19, 33] ). Interestingly, our data did not support a role for FGF10 in inducing branching in the human fetal lung at any of the stages studied (10-14 weeks). Instead, exposure resulted in cyst formation in pseudoglandular-stage lung explants. A previous study showed that both FGF7 and FGF10 induced fluid secretion and increased intraluminal volume in vitro in first-trimester human fetal explants cultured in Matrigel [34] . We also observed that FGF7 and FGF9 induced cyst formation in 10-12-week human explants, similar to mice [7, 10, 33] . Although human explants had a tendency to form some cysts even in the absence of FGFs, the cysting was much more pronounced in the presence of FGF ligands and completely absent following treatment with FGF inhibitor, suggesting that the cysting effect observed is due to the FGF activity. Fgf10 controls proximal-distal patterning in the mouse lung by preventing the differentiation of epithelial Sox9 progenitors into Sox2-expressing airway cells [5, 6] . We, and others, have recently shown that distal tip buds in the early human lung coexpress SOX2 and SOX9 as opposed to only SOX9 in mice [16, 35, 36] . Moreover, we showed that the maintenance of this double-positive population is required for branching morphogenesis [16] . Here, our results demonstrated that FGF10 impaired the balance and colocalization of SOX2/SOX9 and impaired branching in the early (10-12 weeks) human lung. A recent study found that the treatment of human fetal lung bud tip organoids with FGF7/retinoic acid/CHIR-99021 was enough to support growth (budding) and maintenance of the cultures as well as their progenitor cell population coexpressing SOX2 and SOX9, suggesting that FGF10 is dispensable at this stage of development [35] . This is consistent with our study showing that FGF10 does not induce branching in explant cultures. Another study using in vitro human lung organoids with a combination of seven factors (FGF7, FGF10, NOGGIN, RSPO1, EGF, CHIR99021, and SB431542) demonstrated that these organoids can grow, self-renew, and branch following several weeks in culture. Removal of FGF10 alone from the culture media had no effect on organoid self-renewal or the expression of SOX2 and SOX9 [36] . The presence of FGF7, FGF9, or FGF10 resulted in an increase of SOX9 and a decrease in SOX2 expression in our cultures (Figure 4B-D) . In contrast, inhibition of FGF signaling resulted in increased SOX2 and decreased SOX9 expression. We also showed that the balance of the SOX2/SOX9 double-positive progenitor population appears to be controlled by the maintenance of SMCs in the cultured explants. In response to FGF7, FGF9, and FGF10, we observed a significant decrease in SMC differentiation in the explant cultures, which likely caused an imbalance in SOX2/SOX9 double-positive progenitors and, thus, impaired branching. Primary cultured fibroblasts failed to differentiate to SMCs in the presence of FGF9. While FGF9 has been shown to induce Fgf10 expression in mouse lung cultures [10] , the opposite is true in human lung explants.
FGF ligands are known mitogenic factors in several organ systems, including the lung. Previous studies have shown that FGF7 promotes proliferation of lung epithelium in vitro [7] , whereas a lack of Fgf9 decreases cell proliferation as assessed by BrdU incorporation [21] . In our culture model, using Ki67 staining, we did not see a difference in either epithelial or mesenchymal cell proliferation in the presence of FGF7, FGF9, or FGF10 despite detectable activation of ERK MAPK. The lack of effect of the FGF ligands on proliferation is likely due to timing and scale as the human lung requires a longer time to proliferate and grow compared to rodent lungs. Despite this lack of proliferation, FGF7 and FGF9 were able to induce the expression of several known FGF-signaling target genes (ETV4, ETV5, SPRTY2, SPRTY4 and DUSP6). In contrast, FGF10 failed to significantly modulate any of these targets. In mice, Fgf10 induces SFTPC expression (distal fate) in the tracheal epithelium in vitro [28] . We showed that SFTPC is absent in the human lung at early stages of development, which could explain the lack of modulation of other target genes. This lack of target gene modulation could also be determined by whether or not tyrosine (Y) 734 of FGFR2b is phosphorylated in response to FGF10. This in turn would respectively cause the receptor to be endocytosed resulting in activation of the PI3K/AKT pathway or alternatively result in degradation of the receptor [37] . Moreover, the affinity of the FGFs to heparin sulfate can regulate the extent of the cell response to a specific FGF [38] . In contrast, global inhibition of FGF signaling using the SU5402 inhibitor stopped branching in the human fetal explants, and cells acquired a SOX2+ (proximal) fate. This suggests that FGF signaling is important for lung branching, perhaps in a different manner than it is in mice. We stipulate that the preservation of the proximal-distal axis by balanced FGF signaling is also important in human lung branching, but perhaps different ligands/receptors are involved in this process in humans. This is the first comprehensive study on the role of FGF signaling in human fetal lung. A fully developed mouse lung contains 13 generations of branches, while a human lung contains 23. In addition to size and scale, a major structural difference between mouse and human airway composition has been described: cartilaginous airways are restricted in the mouse lung to the trachea and main bronchi, while in the human lung they extend to the terminal bronchioles. Moreover, timing differences between the human and mouse are complex, have not fully been defined, and could contribute to the discrepant observations about the role of FGF10 in lung development. While structural differences between mouse and human, together with our data, suggest that observed differences in the effect of FGF10 may not be solely based on timing, we cannot formally rule out a role for timing as well. Our results provide evidence that FGF10 has a different role in human versus mouse lung, and although some FGFs (FGF9) play a similar physiological role, the molecular pathways driving it may differ. Further studies aiming to elucidate the cellular and molecular targets of the different FGFs and their receptors in the developing human lung are needed in order to address a gap of knowledge. This in turn will accelerate the translational potential of animal studies and open the way to better therapeutic insight for the use of individual FGFs to treat human diseases.
